Literature DB >> 1849727

In vitro incubation with influenza virus primes human polymorphonuclear leukocyte generation of superoxide.

W W Busse1, R F Vrtis, R Steiner, E C Dick.   

Abstract

Viral respiratory illnesses exacerbate asthma, increase airway responsiveness, and enhance the frequency of late asthmatic reactions. A number of mechanisms have been identified to explain how respiratory viral illnesses provoke wheezing, including enhanced inflammatory activity of leukocytes. To further understand how respiratory virus-caused illnesses promote leukocyte-dependent airway injury, the following study evaluated the effect of an in vitro incubation of influenza A virus on human polymorphonuclear leukocyte (PMN) generation of superoxide (O2-). PMNs were isolated from anticoagulated human blood following density gradient centrifugation; purified PMNs were then incubated (37 degrees C x 30 min) with influenza virus (PMN:virus ratio of 5:1 [egg-infective dose 50%] and 10:1) in the presence of 10% autologous serum. After incubation, the viable PMNs (greater than 95% exclusion of trypan blue) were activated, by the chemotactic peptide formyl-methionine-leucine-phenylalanine (fMLP), calcium ionophore A23187, or phorbol myristate acetate (PMA), and O2- generation was then measured. Generation of O2- to fMLP and A23187 was significantly enhanced from PMNs that had been incubated with influenza virus. Although influenza virus itself did not generate O2-, it caused a transient increase in intracellular calcium ([Ca2+]i), when measured with Indo-1-loaded cells. These results suggest that influenza virus primes PMNs to generate increased amounts of O2- and that the priming effect is associated with a transient increase in [Ca2+]. Consequently, we postulate that influenza virus priming produces PMNs of enhanced inflammatory potential to cause greater airway injury, obstruction, and responsiveness during a viral respiratory infection.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1849727     DOI: 10.1165/ajrcmb/4.4.347

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  7 in total

1.  Influenza A infection enhances antigen-induced airway inflammation and hyperresponsiveness in young but not aged mice.

Authors:  J M Birmingham; V L Gillespie; K Srivastava; X-M Li; P J Busse
Journal:  Clin Exp Allergy       Date:  2014-09       Impact factor: 5.018

2.  Effects of parainfluenza type 3 virus on guinea pig pulmonary alveolar macrophage functions in vitro.

Authors:  P A Henricks; B Van Esch; F Engels; F P Nijkamp
Journal:  Inflammation       Date:  1993-12       Impact factor: 4.092

Review 3.  Does influenza vaccination exacerbate asthma?

Authors:  C L Park; A Frank
Journal:  Drug Saf       Date:  1998-08       Impact factor: 5.606

Review 4.  Association of rhinovirus infections with asthma.

Authors:  J E Gern; W W Busse
Journal:  Clin Microbiol Rev       Date:  1999-01       Impact factor: 26.132

5.  CXCR2 is required for neutrophilic airway inflammation and hyperresponsiveness in a mouse model of human rhinovirus infection.

Authors:  Deepti R Nagarkar; Qiong Wang; Jee Shim; Ying Zhao; Wan C Tsai; Nicholas W Lukacs; Uma Sajjan; Marc B Hershenson
Journal:  J Immunol       Date:  2009-10-28       Impact factor: 5.422

6.  Global host immune response: pathogenesis and transcriptional profiling of type A influenza viruses expressing the hemagglutinin and neuraminidase genes from the 1918 pandemic virus.

Authors:  John C Kash; Christopher F Basler; Adolfo García-Sastre; Victoria Carter; Rosalind Billharz; David E Swayne; Ronald M Przygodzki; Jeffery K Taubenberger; Michael G Katze; Terrence M Tumpey
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

Review 7.  Mechanisms of virus-induced asthma exacerbations: state-of-the-art. A GA2LEN and InterAirways document.

Authors:  N G Papadopoulos; P Xepapadaki; P Mallia; G Brusselle; J-B Watelet; M Xatzipsalti; G Foteinos; C M van Drunen; W J Fokkens; C D'Ambrosio; S Bonini; A Bossios; Jan Lötvall; P van Cauwenberge; S T Holgate; G W Canonica; A Szczeklik; G Rohde; J Kimpen; A Pitkäranta; M Mäkelä; P Chanez; J Ring; S L Johnston
Journal:  Allergy       Date:  2007-02-27       Impact factor: 13.146

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.